NAVIGATING OPPORTUNITIES: PHARMA & HEALTHCARE



Overview of the Indian Pharma Sector:

The Indian Pharma Industry holds a significant global position, commanding the production of generic medicines and supplying a substantial portion of vaccines and medications worldwide. Renowned internationally for its affordable drugs and vaccines, India's pharmaceutical industry has experienced dynamic growth in the past. Currently, it stands as the third-largest producer by volume and the 14th-largest by value in the global pharmaceutical landscape. Contributing around 1.72% to the nation's GDP*, the sector's transformation has been remarkable



Future Prospects:



The pharmaceutical sector may grow from here due to several key factors. Icreased global demand for medications, especially generic drugs, presents a significant opportunity for Indian pharmaceutical companies. The sector's focus on research and development, along with advancements in technology, can lead to the discovery of new molecules and innovative treatments, fostering competitiveness. Additionally, India's cost-effective manufacturing capabilities and skilled workforce provide a competitive advantage, while the easing of regulatory challenges and improved compliance pave the way for accelerated approvals and expansion into international markets.

Proposal in Brief:

Following its underperformance in CY 2022, the Pharma sector-oriented funds have rebounded impressively. The historical track record of the pharma sector in generating wealth for investors makes it an appealing option. Investors willing to embrace a slightly higher risk profile might find investing in Pharma Sectorial Funds a viable consideration.



Shreeniwas Gadiyar, Retirement + Estate Planning Advisor
AMFI-Registered Mutual Fund Distributor + SIF Distributor | ARN-56618
gadiyar@planyourdreams.in 9833570575 www.planyourdreams.in

PHARMA & HEALTHCARE FUNDS CATEGORY PERFORMANCE

Category	1 Year	3 Year	5 Year	10 Year
Equity-Sector Pharma&Health	23.17	15.32	16.39	15.15

SIP PERFORMACE OF TOP 3 SCHEMES:



Scheme Name	Monthly SIP Amount	SIP Start Date	SIP End Date	Amount Invested	Value as on 01/09/2023	Profit / Loss 01/09/2023
A	₹10,000	01/01/2013	01/08/2023	₹12,80,000	₹30,95,613	₹18,15,613
B	₹10,000	01/01/2013	01/08/2023	₹12,80,000	₹27,99,162	₹15,19,162
C	₹10,000	01/01/2013	01/08/2023	₹12,80,000	₹25,56,392	₹12,76,392

LUMPSUM PERFORMACE OF TOP 3 SCHEMES




Scheme Name	Lumpsum Amount	Investment Date	Value as on 01/09/2023	Profit / Loss	XIRR Return
A	₹10,00,000	01/01/2013	₹49,39,266	₹39,39,266	16.15%
B	₹10,00,000	01/01/2013	₹45,76,568	₹35,76,568	15.32%
C	₹10,00,000	01/01/2013	₹37,63,153	₹27,63,153	13.32%

Shreeniwas Gadiyar, Retirement + Estate Planning Advisor
AMFI-Registered Mutual Fund Distributor | SEBI Registered Distributor | ARN-56628
gadiyar@planyourdreams.in 9833570575 www.planyourdreams.in

Risk:

The stock markets display volatility, with sector-focused equity funds presenting elevated levels of risk. There might be instances of drawdowns, necessitating investor readiness. If you possess a strong risk tolerance, consider opting for investment in Lumpsum or SIP in a Pharma & Healthcare Oriented Mutual Fund.





Final Thoughts:

The past journey of the Indian pharmaceutical sector has been exceptional, marked by significant growth fueled by both international and domestic demands. By prioritizing innovation, venturing into unexplored markets, and harnessing emerging prospects in areas like drug delivery and personalized medicine, the industry may be well-poised to sustain its impressive trajectory and may uphold its pivotal role in shaping the global healthcare landscape for years to come.



Disclaimer: Mutual Fund investments are subject to market risk. Please read the scheme related documents carefully before investing. The report has been compiled using the data at our disposal, and we have exercised utmost caution to prevent any errors or oversights. It's important to note that past performance might not be indicative of future results. Return below one year period is XIRR and above one year is annualised. **Report date - 15/09/2023**

**Source: IBEF.ORG*

Shreeniwas Gadiyar, Retirement + Estate Planning Advisor
AMFI-Registered Mutual Fund Distributor + SIF Distributor | ARN-56618
gadiyar@planyourdreams.in 9833570575 www.planyourdreams.in